Author: admin

Baker McKenzie rendered comprehensive legal advice to Innovative Molecules GmbH (“Innovative Molecules”), a Munich-based biotechnology company, on a strategic partnership with the Italian pharmaceutical company Alfasigma S.p.A. (“Alfasigma”). In addition to an investment element, the partnership includes the exclusive worldwide license to the parenteral formulation of adibelivir (formerly IM 250) for the treatment of Herpes Simplex Virus (HSV) encephalitis. Innovative Molecules retains full rights to all other formulations, including the oral formulation, which is currently advancing towards Phase II development for the treatment of genital herpes.

The contractually agreed financial license terms include payments of up to €125 million in upfront and milestone payments, triggered by development progress, regulatory approvals, and global commercial milestones.

“We are very pleased to have accompanied Innovative Molecules in this strategically important transaction. The partnership with Alfasigma not only strengthens the development of a much-needed innovative therapeutic approach, but also underlines the increasing importance of cross-border life science collaborations that reflect investment interests as well as IP transactions and collaborations,” commented Julia Braun, lead partner of the transaction.

Baker McKenzie’s corporate/M&A and life sciences teams regularly advise pharmaceutical companies, financial investors, strategic investors and biotechnology companies on national and international transactions in the life sciences sector. Most recently, Baker McKenzie advised inter alia GIMV, EQT Life Sciences, Fountain Healthcare and LifeArc Ventures on a EUR 50 million Series B2 financing of Exciva GmbH, Bristol Myers Squibb on the transfer of Juno Therapeutics GmbH to TQ Therapeutics GmbH, ATB Therapeutics on a EUR 54 million Series A financing, EQT Life Sciences on a EUR 128 million Series B2 financing of Tubulis GmbH, KD Pharma Group on the acquisition of the marine lipids business from dsm-firmenich in exchange for a minority stake in the company and Mitsubishi Tanabe Pharma on the sale of the European Argatroban business to Ethypharm.

Legal adviser to Innovative Molecules:
Baker McKenzie

Lead:
Corporate/M&A: Julia Braun LL.M. (partner, Munich), Dr. Julia Rossié (senior associate, Munich)

Team:
Corporate/M&A: Erik Kuhn (associate, Munich)
Transactional IP: Oren Livne (partner, New York), Patrick H. Wilkening (partner, Düsseldorf), Yannick Filoda (associate, Düsseldorf)
Antitrust/Competition: Jan Kresken LL.M. (partner, Düsseldorf), Dr. Florian Kotman LL.M. (counsel, Düsseldorf)
Banking & Finance: Prof. Dr. Artur M. Swierczok LL.M. (counsel, Frankfurt)
Pharma: Dr. Martin Altschwager LL.M. (partner, Frankfurt), Anna Fischer (associate, Frankfurt)
FDI: Frederik Alexander Dörr (associate, Berlin)